Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 …
Nov 15, 2022 · Methods: JNJ-80948543 is a fully human immunoglobulin G1 trispecific antibody composed of an anti-CD3ɛ single-chain variable fragment (scFv), an anti-CD20 scFv, and an …
JNJ-8543 by Johnson & Johnson for Follicular Lymphoma: …
Jan 19, 2025 · JNJ-8543 overview. JNJ-80948543 is under development for the treatment of chronic lymphocytic leukemia (CLL), waldenstrom macroglobulinemia (lymphoplasmacytic …
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell …
3 days ago · The purpose of this study is to determine the recommended phase 2 regimen (RP2R) for JNJ-80948543 in combination with JNJ-75348780 (Part 1: Dose Escalation) and to …
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x
Mar 5, 2025 · The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of …
A phase 1, first-in-human study of JNJ-80948543, a T-cell …
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ …
J&J, flush with blood cancer assets, cuts one from the pipeline
Oct 18, 2022 · In May, VAC85135 received a green light from the FDA to launch into clinical trials and recruitment is ongoing. J&J also added JNJ-8543 to the roster, another phase 1 blood …
A Phase 1 Study of JNJ-80948543 Immunotherapy in People with …
The purpose of this study is to find the highest dose of JNJ-80948543 immunotherapy that can be given safely in people with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia …
JNJ-80948543 - Drug Targets, Indications, Patents - Synapse
3 days ago · In May, VAC85135 received a green light from the FDA to launch into clinical trials and recruitment is ongoing. J&J also added JNJ-8543 to the roster, another phase 1 blood …
JNJ-8543 Trials - LARVOL Sigma
jnj-8543 / j&j NCT06139406: A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer Recruiting
JNJ-8543 / J&J - LARVOL
Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma (ASH 2022) - "Taken together, …
- Some results have been removed